Conshohocken, PA – Founded in 2023, Tiger BioSciences LLC has rapidly emerged as one of the most vertically integrated companies in the regenerative medicine and medical-technology landscape. Based just outside Philadelphia, the firm operates a network of divisions spanning donor tissue recovery, advanced processing, R&D, manufacturing, and global distribution—positioning itself as a full-spectrum provider of cellular, acellular, and matrix-like products (CAMPs) for wound care, soft-tissue reconstruction, and aesthetics.
A Rapid Ascent Since 2023
Tiger BioSciences was founded by Scott Madden and Oliver Burckhardt, both experienced executives in medical devices and tissue-based therapeutics. Their shared vision was to close the gap between donor-tissue recovery and clinical application by creating a seamless, end-to-end platform.
Within two years, the company has scaled from a startup concept to a multi-divisional enterprise with operations in tissue processing, product development, and global logistics. According to public business data, Tiger BioSciences employs several hundred people and records estimated revenues in the tens of millions annually.
While still privately held, the company has pursued aggressive growth through acquisitions and infrastructure investments, signaling ambitions well beyond early-stage medtech norms.
A Vertically Integrated Model
The company describes its approach as “fully integrated from donor to delivery.” Each division contributes a piece of that ecosystem:
- Tiger Wound Care focuses on regenerative matrices and CAMP products for chronic and complex wounds.
- Tiger Aesthetics develops biologically inspired solutions for reconstructive and cosmetic surgery, including regenerative breast tissue scaffolds and implant technologies.
- RegenTX and BioCare serve as the R&D and innovation arms, advancing tissue-processing and preservation science.
- Tiger International handles overseas distribution and regulatory coordination for global markets.
This model allows the company to maintain control over tissue sourcing, regulatory compliance, and manufacturing quality—capabilities that most peers outsource. It also provides a degree of insulation from supply-chain disruptions that have affected many post-pandemic biomanufacturers.
Scaling Through Manufacturing and Acquisitions
In 2024, Tiger Aesthetics (a division of Tiger BioSciences) acquired the assets of Sientra Inc., a California-based breast-implant company, giving it immediate access to product lines, regulatory clearances, and established distribution networks.
Shortly after, the company announced a $50 million investment to expand its manufacturing footprint in Franklin, Wisconsin, converting a 120,000-square-foot facility into a next-generation production site for regenerative and aesthetic implants. The new plant is expected to double its workforce by 2028 and integrate advanced automation for tissue processing and packaging.
Why It Matters
Tiger BioSciences’ growth underscores a broader trend in regenerative medicine—companies moving from niche R&D ventures to integrated, industrial-scale platforms. By bridging donor recovery, biomaterial processing, and clinical distribution, Tiger is effectively constructing an internal ecosystem that mirrors the structure of larger device manufacturers while maintaining a regenerative-medicine focus.
This integration could allow the company to move faster on innovation cycles, reduce dependency on contract manufacturers, and accelerate regulatory filings for novel biologically derived devices.
Check out the video below for a flavor of the work:
About Tiger BioSciences
Website: tigerbiosciences.com
Tiger BioSciences develops and manufactures advanced biologic and tissue-based products for wound healing, reconstructive surgery, and regenerative medicine. Its integrated approach spans tissue donor screening, processing, product development, and worldwide distribution.
The Business of Biofabrication 
Leave a comment